Search for Clinical Trial Results
Cutaneous T-cell Lymphoma - 27 Studies Found
Status | Study |
Completed |
Study Name: A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2008-08-29 Interventions: Drug: Enzastaurin 1125 mg loading dose then 500 mg, oral, daily, until disease progression |
Completed |
Study Name: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study Condition: Cutaneous T-Cell Lymphoma Date: 2008-10-22 Interventions: Drug: Tazarotene Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase |
Recruiting |
Study Name: Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Condition: Cutaneous T-cell Lymphoma Date: 2014-02-11 Interventions:
|
Withdrawn |
Study Name: Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) Condition: Cutaneous T-cell Lymphoma (CTCL) Date: 2013-04-24 Interventions: Drug: Sirolimus 0.1% Ointment Sirolimus 0.1% ointment will be applied topically to all affected areas of |
Active, not recruiting |
Study Name: Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2012-07-15 Interventions:
|
Completed |
Study Name: Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Condition: Cutaneous T-Cell Lymphoma Date: 2006-03-23 Interventions:
|
Completed |
Study Name: A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) Condition: Cutaneous T-cell Lymphoma Date: 2005-03-24 Interventions: Drug: romidepsin (depsipeptide, FK228) Study patients received romidepsin at a dose of 14 mg/m^2 intrave |
Recruiting |
Study Name: Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) Condition: Cutaneous T-Cell Lymphoma Date: 2015-10-29 Interventions: Biological: IPH4102 |
Recruiting |
Study Name: Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) Condition: Cutaneous T Cell Lymphoma Date: 2015-09-06 Interventions: Drug: dimethylfumarate dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design i |
Completed |
Study Name: Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Condition: Refractory Cutaneous T-cell Lymphoma Date: 2009-11-03 Interventions:
|